# Cambridge Cognition Holdings Plc NeuroVocalix™ platform ready for clinical trials

- Link: https://www.directorstalkinterviews.com/cambridge-cognition-holdings-plc-neurovocalix-platform-ready-for-clinical-trials/412758383
- Published: 2018-09-13T07:12:00+01:00
- Author: Giles Arbor

**Cambridge Cognition Holdings plc** ([LON:COG](https://www.directorstalkinterviews.com/company/cambridge-cognition-holdings-plc/cog.l)),
the neuroscience technology company which develops and markets digital solutions
to assess brain health, has today announced its voice biomarker and AI platform,
NeuroVocalix™, for use in clinical trials.

Having filed patents and announced the start of the technology programme last year,
the Company has now confirmed its first voice-based cognitive assessments are available
for use in its core pharmaceutical and biotechnology clinical trial channels.

NeuroVocalix enables novel voice-based cognitive assessments to be delivered directly
to patients through mobile and tele-health platforms, helping to improve outcomes
in clinical trials, aid clinical decision-making and play an important role in the
management of long-term conditions such as chronic pain.

Data presented today at Intelligent Health in Basel demonstrates the new technology’s
ability to use AI to derive voice biomarkers, which can objectively measure mental
states.

One major use of this technology is likely to be in the objective voice-based measurement
of pain. Chronic pain is a major unmet medical need, affecting around 1 in 3 people
worldwide and costing €441 billion per year in Europe1 and $560-635 billion per 
year in the USA2. Insufficient pain relief increases personal suffering and is a
major cause for premature exit from the labour market, and increases risk of other
health problems, social exclusion and poverty.

While many treatments for pain are available, they do not work for everyone and 
often have undesirable side effects. The lack of objective measurement of pain poses
a major barrier to developing better treatments of pain control.

NeuroVocalix is designed to elicit and automatically analyse pain-related signals
in human voice. This will provide an innovative, objective means of measuring pain
for use in clinical trials as a more accurate assessment of a drug’s effects and
eventually in clinical practice where it will support appropriate prescribing and
performance-based reimbursement.

This broadly applicable machine-learning platform is already generating interest
from digital health companies specialising in areas ranging from pain to Parkinson’s
disease and psychiatry with the first commercial partnerships expected in 2018.

> **Dr Steven Powell, Chief Executive Officer, Cambridge Cognition Holdings plc 
> said:** “This new platform is a key step in the Company’s strategy for growth;
> developing innovative near-patient digital technologies to optimise drug development
> and patient health outcomes. Voice biomarker data provides our commercial partners
> with additional insights into drug treatment outcomes and compliments our mobile,
> wearable and web-based digital health technologies in assessing cognition and 
> brain health anytime, anywhere.”

**References**

1 The Societal Impact of Pain Platform, 2017, Impact of Pain on Society Costs the
EU up to 441 Billion Euros Annually. Available from: https://www.sip-platform.eu/
press-area/article/impact-of-pain-on-society-costs-the-eu-up-to-441-billion-euros-
annually

2 Gaskin DJ, Richard P. The Economic Costs of Pain in the United States. In: Institute
of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Relieving
Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research.
Washington (DC): National Academies Press (US); 2011. Appendix C. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK92521/

Share on:
